Aerosolized medications for gene and peptide therapy

Respiratory Care

Volumn 60, Issue 6, 2015, Pages 806-821

  Laube, Beth L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Aerosol non viral vectors; Aerosol viral vectors; Alpha 1 antitrypsin; Cystic fibrosis (CF); Glutathione (GSH); Granulocyte macrophage colony stimulating factor (GM CSF); Insulin; Interfering RNA; Lung cancer; Vasoactive intestinal peptide

Indexed keywords

AEROSOLIZED PEPTIDE; ALPHA 1 ANTITRYPSIN; CALCITONIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLUTATHIONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INSULIN; LIPOSOME; NANOPARTICLE; PEPTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VIRUS VECTOR; AEROSOL; NUCLEIC ACID;

AEROSOL; ALPHA 1 ANTITRYPSIN GENE; ALPHA ANTITRYPSIN DEFICIENCY; ARTICLE; ASTHMA; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; GENE; GENE THERAPY; HUMAN; LUNG ALVEOLUS PROTEINOSIS; LUNG CANCER; LUNG SARCOIDOSIS; MYCOBACTERIUM TUBERCULOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PULMONARY HYPERTENSION; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; PROCEDURES;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; LUNG DISEASES; NUCLEIC ACIDS; PEPTIDES;

EID: 84944729759     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.03554     Document Type: Article

References (141)

1. Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. Mol Ther 2009;17(5):767-777.
2. Mali S. Delivery systems for gene therapy. Indian J Hum Genet 2013;19(1):3-8.
3. Zarogouldis P, Karamanos NK, Porpodis K, Domvri K, Huang H, Hohenforst-Schmidt W, et al. Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology. Int J Mol Sci 2012;13(9):10828-10862.
4. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005;50(9):1161-1176.
5. Pichon C, Billiet L, Midoux P. Chemical vectors for gene delivery: uptake and intracellular trafficking. Curr Opin Biotechnol 2010; 21(5):640-645.
6. Griesenbach U, Alton EW. Expert opinion in biological therapy: update on developments in lung gene transfer. Expert Opin Biol Ther 2013;13(3):345-360.
7. Griesenbach U, Alton EW. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Pharm Des 2012;18(5):642-662.
8. Yasuda S, Yoshida H, Nishikawa M, Takakura Y. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages. Mol Pharm 2010;7(2):533-542.
9. Goodsell D. Small interfering RNA (siRNA). RCSB PDB-101, 2008. http://www.rcsb.org/pdb/101/motm.do?momID_98&print_1. Accessed May 12, 2014.
10. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26(2):199-213.
11. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res 2002;30(8):1757-1766.
12. Caplen NJ. RNAi as a gene therapy approach. Expert Opin Biol Ther 2003;3(4):575-586.
13. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16(8):948-958.
14. McManus MT, Petersen CP, Haines BB, Chen J, Sharp PA. Gene silencing using micro-RNA designed hairpins. RNA 2002;8(6):842-850.
15. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009;61(9):746-759.
16. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 2003;278(9):7108-7118.
17. Aoki Y, Cioca DP, Oidaira H, Kamiya J, Kiyosawa K. RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol 2003;30(1-2):96-102.
18. Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 2003;13(1):1-7.
19. Tong AW, Zhang YA, Nemunaitis J. Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 2005;7(2):114-124.
20. Novello S, Longo M, Levra MG. Toward therapies tailored to patient characteristics. J Thorac Oncol 2007;2(5 Suppl):S38-S41.
21. Subramanian J, Waqar SN, Govindan R. Targeted therapy in lung cancer: lessons learned from past experiences. J Thorac Oncol 2011; 6(11 Suppl 4):S1786-S1788.
22. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-98.
23. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6(8):583-592.
24. Tatsumura T, Yamamoto K, Murakami A, Tsuda M, Sugiyama S. [New chemotherapeutic method for the treatment of tracheal and bronchial cancers—nebulization chemotherapy]. Gan No Rinsho 1983;29(7):765-770. Article in Japanese.
25. Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 1993;68(6):1146-1149.
26. Gautam A, Koshkina N. Paclitaxel (Taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets 2003;3(4):287-296.
27. Hershey AE, Kurzman ID, Forrest LJ, Bohling CA, Stonerook M, Placke ME, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 1999;5(9): 2653-2659.
28. Koshkina NV, Golunski E, Roberts LE, Gilbert BE, Knight V. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 2004;17(1):7-14.
29. Minchin RF, Johnston MR, Aiken MA, Boyd MR. Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo. J Pharmacol Exp Ther 1984;229(1):193-198.
30. Gavini E, Manunta L, Giua S, Achenza G, Giunchedi P. Spraydried poly(D,L-lactide) microspheres containing carboplatin for veterinary use: in vitro and in vivo studies. AAPS PharmSci Tech 2005;6(1):E108–E114.
31. Khanna C, Vail DM. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr Cancer Drug Targets 2003;3(4):265-273.
32. Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 2008;21(1):61-70.
33. Selting K, Waldrep JC, Reinero C, Branson K, Gustafson D, Kim DY, et al. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Deliv 2008;21(3):255-268.
34. Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus PE. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med 2006;19(3):385-391.
35. Gagnadoux F, Le Pape A, Lemarie´ E, Lerondel S, Valo I, Leblond V, et al. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J 2005;26(4):657-661.
36. Chao P, Deshmukh M, Kutscher HL, Gao D, Rajan SS, Hu P, et al. Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anticancer Drugs 2010;21(1):65-76.
37. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009;30(20):3476-3485.
38. Schäffer MW, Roy SS, Mukherjee S, Ong DE, Das SK. Uptake of all-trans retinoic acid-containing aerosol by inhalation to lungs in a guinea pig model system—a pilot study. Exp Lung Res 2010;36(10): 593-601.
39. Roa WH, Azarmi S, Al-Hallak MH, Finlay WH, Magliocco AM, Löbenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 2011;150(1): 49-55.
40. Hureaux J, Lagarce F, Gagnadoux F, Vecellio L, Clavreul A, Roger E, et al. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm 2009;73(2):239-246.
41. Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. Alpha-TEA plus cisplatin reduces human cisplatinresistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med 2004;229(11):1169-1176.
42. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001;7(10):3258-3262.
43. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 2010;107(23):10737-10742.
44. Wattenberg LW, Wiedmann TS, Estensen RD. Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Cancer Res 2004;64(7):2347-2349.
45. Knight V, Koshkina NV, Golunski E, Roberts LE, Gilbert BE. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. Trans Am Clin Climatol Assoc 2004;115:395-404.
46. Lawson KA, Anderson K, Snyder RM, Simmons-Menchaca M, Atkinson J, Sun LZ, et al. Novel vitamin E analogue and 9-nitrocamptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol 2004;54(5):421-431.
47. El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res 2009;26(7):1752-1763.
48. Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, Löbenberg R, Roa WH. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 2006;319(1-2):155-161.
49. Hitzman CJ, Wattenberg LW, Wiedmann TS. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipidcoated nanoparticles. J Pharm Sci 2006;95(6):1196-1211.
50. Zarogoulidis P, Eleftheriadou E, Sapardanis I, Zarogoulidou V, Lithoxopoulou H, Kontakiotis T, et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest New Drugs 2012; 30(4):1628-1640.
51. Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, Murren JR. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res 2010;16(8):2466-2473.
52. Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 2007;13(4): 1246-1252.
53. Wittgen BP, Kunst PW, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 2007;13(8):2414-2421.
54. Verschraegen CF, Gilbert BE, Loyer E, Huaringa A, Walsh G, Newman RA, Knight V. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004;10(7):2319-2326.
55. Lemarie E, Vecellio L, Hureaux J, Prunier C, Valat C, Grimbert D, et al. Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv 2011;24(6):261-270.
56. Wilda M, Fuchs U, Wössmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002;21(37):5716-5724.
57. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 2003;101(4):1566-1569.
58. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2(3):243-247.
59. Zhang L, Yang N, Mohamed-Hadley A, Rubin SC, Coukos G. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 2003;303(4):1169-1178.
60. Nagy P, Arndt-Jovin DJ, Jovin TM. Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res 2003;285(1):39-49.
61. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003;63(7):1515-1519.
62. World Health Organization. WHO Report 2007. Global tuberculosis control: surveillance, planning, financing. Geneva, Switzerland: World Health Organization; 2007.
63. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp GL, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 2006;12(11):1286-1293.
64. Lomas-Neira JL, Chung CS, Wesche DE, Perl M, Ayala A. In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury. J Leukoc Biol 2005;77(6): 846-853.
65. Matsuyama W, Watanabe M, Shirahama Y, Hirano R, Mitsuyama H, Higashimoto I, et al. Suppression of discoidin domain receptor 1 by RNA interference attenuates lung inflammation. J Immunol 2006;176(3):1928-1936.
66. Zhang X, Shan P, Jiang D, Noble PW, Abraham NG, Kappas A, Lee PJ. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 2004;279(11):10677-10684.
67. Rosas-Taraco AG, Higgins DM, Sánchez-Campillo J, Lee EJ, Orme IM, González-Juarrero M. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am J Respir Cell Mol Biol 2009; 41(2):136-145.
68. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1 antitrypsin deficiency. Am J Med 1988;84(6A):13-31.
69. Kurachi K, Chandra T, Degen SJ, White TT, Marchioro TL, Woo SL, Davie EW. Cloning and sequence of cDNA coding for alpha-1 antitrypsin. Proc Natl Acad Sci USA 1981;78(11):6826-6830.
70. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276(36):33293-33296.
71. Silverman EK, Miletich JP, Pierce JA, Sherman LA, Endicott SK, Broze GJ, Jr, Campbell EJ. Alpha-1 antitrypsin deficiency. High prevalence in the St Louis area determined by direct population screening. Am Rev Respir Dis 1989;140(4):961-966.
72. de Serres FJ. Worldwide racial and ethnic distribution of alpha-1 antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002;122(5):1818-1829.
73. Sandhaus RA. Alpha-1 antitrypsin deficiency. 6: New and emerging treatments for alpha-1 antitrypsin deficiency. Thorax 2004; 59(10):904-909.
74. Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha-1 antitrypsin deficiency by the aerosol route. Lung 1990;168(Suppl): 565-578.
75. Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha-1 antitrypsin deficiency directly augmented with an aerosol of alpha-1 antitrypsin. Ann Intern Med 1989;111(3):206-212.
76. Hubbard RC, McElvaney NG, Sellers SE, Healy JT, Czerski DB, Crystal RG. Recombinant DNA-produced alpha-1 antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha-1 antitrypsin deficiency. J Clin Invest 1989;84(4):1349-1354.
77. Kamada. International study evaluating the safety and efficacy of inhaled, human, alpha-1 antitrypsin (AAT) in alpha-1 antitrypsin deficient patients with emphysema. http://clinicaltrials.gov/show/NCT01217671. Accessed May 22, 2014.
78. Brebner JA, Stockley RA. Recent advances in alpha-1 antitrypsin deficiency-related lung disease. Expert Rev Respir Med 2013;7(3): 213-229.
79. Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, Meyer T. Lung deposition of inhaled alpha-1 proteinase inhibitor in cystic fibrosis and alpha-1 antitrypsin deficiency. Eur Respir J 2009; 34(2):354-360.
80. Geller DE, Kesser KC. The I-neb adaptive aerosol delivery system enhances delivery of alpha-1 antitrypsin with controlled inhalation. J Aerosol Med Pulm Drug Deliv 2010;23(Suppl 1):S55-S59.
81. Dasí F, Benet M, Crespo J, Crespo A, Aliño SF. Asialofetuin liposome-mediated human alpha-1 antitrypsin gene transfer in vivo results in stationary long-term gene expression. J Mol Med 2001; 79(4):205-212.
82. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, et al. Adenovirus-mediated transfer of a recombinant alpha-1 antitrypsin gene to the lung epithelium in vivo. Science 1991;252(5004):431-434.
83. Kay MA, Graham F, Leland F, Woo SL. Therapeutic serum concentrations of human alpha-1 antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 1995;21(3):815-819.
84. Kay MA, Holterman AX, Meuse L, Gown A, Ochs HD, Linsley PS, Wilson CB. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11(2):191-197.
85. Setoguchi Y, Jaffe HA, Chu CS, Crystal RG. Intraperitoneal in vivo gene therapy to deliver alpha-1 antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 1994;10(4):369-377.
86. Levy MY, Barron LG, Meyer KB, Szoka FC Jr. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Ther 1996;3(3):201-211.
87. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998;18(2):180-183.
88. Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, Quinones J, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha-1 antitrypsin with negligible toxicity. Hum Gene Ther 1998;9(18):2709-2716.
89. Zhang D, Wu M, Nelson DE, Pasula R, Martin WJ II. Alpha-1 antitrypsin expression in the lung is increased by airway delivery of gene-transfected macrophages. Gene Ther 2003;10(26):2148-2152.
90. Brigham KL, Lane KB, Meyrick B, Stecenko AA, Strack S, Cannon DR, et al. Transfection of nasal mucosa with a normal alpha-1 antitrypsin gene in alpha-1 antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 2000;11(7):1023-1032.
91. Griesenbach U, Alton EW. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 2009;61(2):128-139.
92. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125(2):509-521.
93. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007;18(8):726-732.
94. Alton EW, Boyd AC, Cheng SH, Cunningham S, Davies JC, Gill DR, et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax 2013;68(11):1075-1077.
95. Griesenbach U, Alton EW. Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 2013;22(R1):R52-R58.
96. Berisha HI, Bratut M, Bangale Y, Colasurdo G, Paul S, Said SI. New evidence for transmitter role of VIP in the airways: impaired relaxation by a catalytic antibody. Pulm Pharmacol Ther 2002; 15(2):121-127.
97. Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 1999;93(1-2):126-138.
98. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001;7(5):563-568.
99. Mathioudakis A, Chatzimavridou-Grigoriadou V, Evangelopoulou E, Mathioudakis G. Vasoactive intestinal peptide inhaled agonists: potential role in respiratory therapeutics. Hippokratia 2013;17(1): 12-16.
100. Said SI. Vasoactive intestinal polypeptide and asthma (editorial). N Engl J Med 1989;320(19):1271-1273.
101. Cardell LO, Uddman R, Edvinsson L. Low plasma concentrations of VIP and elevated levels of other neuropeptides during exacerbations of asthma. Eur Respir J 1994;7(12):2169-2173.
102. Hasaneen NA, Foda HD, Said SI. Nitric oxide and vasoactive intestinal peptide as co-transmitters of airway smooth-muscle relaxation: analysis in neuronal nitric oxide synthase knockout mice. Chest 2003;124(3):1067-1072.
103. Lindén A, Hansson L, Andersson A, Palmqvist M, Arvidsson P, Löfdahl CG, et al. Bronchodilation by an inhaled VPAC2 receptor agonist in patients with stable asthma. Thorax 2003;58(3):217-221.
104. Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T, et al. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 2006;291(5):L880–L886.
105. Groneberg DA, Springer J, Fischer A. Vasoactive intestinal polypeptide as mediator of asthma. Pulm Pharmacol Ther 2001;14(5): 391-401.
106. Said SI. The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann NY Acad Sci 2008;1144:148-153.
107. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111(9):1339-1346.
108. Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 1984;97:304-310.
109. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008;32(5):1289-1294.
110. Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010; 182(4):540-548.
111. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993; 75(6):2419-2424.
112. Roum JH, Borok Z, McElvaney NG, Grimes GJ, Bokser AD, Buhl R, Crystal RG. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 1999;87(1):438-443.
113. Griese M, Ramakers J, Krasselt A, Starosta V, Van Koningsbruggen S, Fischer R, et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 2004;169(7):822-828.
114. Hull J, Vervaart P, Grimwood K, Phelan P. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 1997; 52(6):557-560.
115. Bishop C, Hudson VM, Hilton SC, Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 2005;127(1):308-317.
116. Visca A, Bishop CT, Hilton SC, Hudson VM. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. J Cyst Fibros 2008;7(5): 433-436.
117. Griese M, Kappler M, Eismann C, Ballmann M, Junge S, Rietschel E, et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med 2013;188(1):83-89.
118. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003;349(26):2527-2539.
119. Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegasaki S, Yamada Y, Nakata K. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/ macrophage colony-stimulating factor. J Exp Med 1999;190(6): 875-880.
120. Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000;162(2 Pt 1):658-662.
121. Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ. Autoantibodies against granulocyte macrophage colonystimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002;27(4):481-486.
122. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004;103(3):1089-1098.
123. Reed JA, Ikegami M, Cianciolo ER, Lu W, Cho PS, Hull W, et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999;276(4 Pt 1):L556–L563.
124. Tazawa R, Hamano E, Arai T, Ohta H, Ishimoto O, Uchida K, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005;171(10):1142-1149.
125. Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010;181(12):1345-1354.
126. Wylam ME, Ten R, Prakash UB, Nadrous HF, Clawson ML, Anderson PM. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006;27(3):585-593.
127. Luisetti M, Kroneberg P, Suzuki T, Kadija Z, Muellinger B, Campo I, et al. Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer. Pulm Pharmacol Ther 2011;24(1):123-127.
128. Chestnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109(4):267-276.
129. Vestergaard P, Mosekilde L, Langdahl B. Fracture prevention in postmenopausal women. BMJ Clin Evid 2011;2011:1109.
130. International Diabetes Federation. IDF Diabetes Atlas, 5th edition. http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed Aug 26, 2013.
131. Zarogoulidis P, Petridis D, Ritzoulis C, Li Q, Huang H, Ning Y, et al. Further experimentation of inhaled LANTUS, ACTRAPID and HUMULIN with todays’ production systems. Int J Pharm 2013; 458(1):39-47.
132. Harper NJ, Gray S, De Groot J, Parker JM, Sadrzadeh N, Schuler C, et al. The design and performance of the Exubera pulmonary insulin delivery system. Diabetes Technol Ther 2007;9(Suppl 1): S16-S27.
133. Cefalu WT, Wang ZQ. Clinical research observations with use of Exubera in patients with type 1 and type 2 diabetes. Diabetes Technol Ther 2007;9(Suppl 1):S28-S40.
134. Wollmer P, Pieber TR, Gall MA, Brunton S. Delivering needle-free insulin using the AERx IDMS (insulin diabetes management system) technology. Diabetes Technol Ther 2007;9(Suppl 1):S57-S64.
135. Muchmore DB, Silverman B, De La Peña A, Tobian J. The AIR inhaled insulin system: system components and pharmacokinetic/ glucodynamic data. Diabetes Technol Ther 2007;9(Suppl 1):S41-S47.
136. Ellis SL, Gemperline KA, Garg S. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther 2007;9(Suppl 1):S48-S56.
137. Laube BL. The expanding role of aerosol in systemic drug delivery, gene therapy and vaccination: an update. Transl Respir Med 2014; 2:3.
138. Rosenstock J, Bergenstal R, DeFronzo RA, Hirsch IB, Klonoff D, Boss AH, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008;31(11):2177-2182.
139. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010;375(9733):2244-2253.
140. Neumiller JJ, Campbell RK, Wood LD. A review of inhaled Technosphere insulin. Ann Pharmacother 2010;44(7-8):1231-1239.
141. Lastow O. 2nd Medicon Valley Inhalation Symposium, 16 October 2013, Lund, Sweden. Ther Deliv 2014;5(2):119-121.